Literature DB >> 7648786

Plasma endothelin levels in NIDDM patients with macroangiopathy.

M Donatelli1, I Colletti, M L Bucalo, V Russo, S Verga.   

Abstract

To determine whether plasma endothelin, a potent vasoconstrictive peptide, is elevated in NIDDM patients, we compared a group of 15 NIDDM patients with macroangiopathy of mean age 60.60 +/- 2.33 years with 15 NIDDM randomly selected matched patients without macroangiopathy. Plasma endothelin levels were significantly increased in NIDDM patients with macroangiopathy (4.22 +/- 0.57 pmol/L) and in NIDDM patients without macroangiopathy (3.81 +/- 0.51 pmol/L). Although endothelin values did not differ between NIDDM groups, both represented significant difference from control values (2.46 +/- 0.24 pmol/L). No significant correlations were found between plasma endothelin and age (rs = 0.11), duration of diabetes mellitus (rs = 0.06), BMI (rs = 0.19), plasma glucose (rs = 0.15), plasma fructosamine (rs = 0.02). These findings confirm that in diabetes mellitus a primary disturbance in endothelin production from vascular endothelium exists as an early phenomenon rather than a result of advanced stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7648786

Source DB:  PubMed          Journal:  Diabetes Res        ISSN: 0265-5985


  12 in total

Review 1.  Role of endothelin in diabetic vascular complications.

Authors:  H C Lam
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

2.  Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation.

Authors:  Giuseppe Faraco; Ana Moraga; Jamie Moore; Joseph Anrather; Virginia M Pickel; Costantino Iadecola
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

3.  Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease.

Authors:  M Donatelli; E Hoffmann; I Colletti; G Andolina; V Russo; M L Bucalo; T M Valenti; V Compagno; M G Cataldo; M L Morici
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

Review 4.  Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

Authors:  Peter N Van Buren; Robert Toto
Journal:  Adv Chronic Kidney Dis       Date:  2011-01       Impact factor: 3.620

Review 5.  The connection between GRKs and various signaling pathways involved in diabetic nephropathy.

Authors:  Feng-Ling Wang; Li-Qin Tang; Wei Wei
Journal:  Mol Biol Rep       Date:  2012-02-21       Impact factor: 2.316

6.  Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers.

Authors:  Anders Hougaard; Samaira Younis; Afrim Iljazi; Kristian A Haanes; Ulrich Lindberg; Mark B Vestergaard; Faisal M Amin; Kazutaka Sugimoto; Lars S Kruse; Cenk Ayata; Messoud Ashina
Journal:  J Cereb Blood Flow Metab       Date:  2019-09-09       Impact factor: 6.200

7.  The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis.

Authors:  Bulent Degertekin; Seren Ozenirler; Sehri Elbeg; Gulen Akyol
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

8.  Decreased NO signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the ZDF rat prior to overt diabetes and hypertension.

Authors:  Lisa A Lesniewski; Anthony J Donato; Bradley J Behnke; Christopher R Woodman; M Harold Laughlin; Chester A Ray; Michael D Delp
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-02-01       Impact factor: 4.733

9.  Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes.

Authors:  Nikolaos Ostlund Papadogeorgos; Mattias Bengtsson; Majid Kalani
Journal:  Vasc Health Risk Manag       Date:  2009-11-02

Review 10.  The importance of endothelin-1 for microvascular dysfunction in diabetes.

Authors:  Majid Kalani
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.